Another strategy is to treat emergent ESR1 mutation before clinical progression with a SERD, as seen in the PADA-1 trial, which assessed palbociclib plus ET, with a switch from an aromatase inhibitor to fulvestrant when ESR1 mutation was detected in circulating tumor DNA [55]. The gene discussed is CYP19A1; the disease is neoplasm.